Procainamide Challenge for Brugada Syndrome: Establishing Diagnostic Safety and the Reassuring Prognosis of Induced Patterns
Posted inCardiology news

Procainamide Challenge for Brugada Syndrome: Establishing Diagnostic Safety and the Reassuring Prognosis of Induced Patterns

A large-scale registry study confirms that procainamide infusion is exceptionally safe for Brugada syndrome diagnosis, with high sensitivity and specificity. Crucially, asymptomatic patients with a procainamide-induced type 1 pattern demonstrate a very low risk of future arrhythmic events, potentially guiding more conservative management strategies.
Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial
Posted inCardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.
Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM
Posted inCardiology news

Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM

This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offering a simple yet powerful tool for clinical cardiopulmonary exercise testing.
A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
Posted inCardiology news

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic peptides, provides a robust staging system across multiple assay platforms.
Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage
Posted inCardiology Emergency Medicine news

Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage

A secondary analysis of the APACE study demonstrates that Cardiac Myosin-Binding Protein C (cMyC) significantly improves NSTEMI diagnosis, particularly in early presenters. Integrating cMyC with high-sensitivity troponin into a dual-biomarker strategy doubles triage efficacy without compromising safety, offering a robust tool for busy clinical settings.
Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease
Posted inCardiology Diabetes & Endocrinology news

Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease

This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesity, highlighting benefits beyond traditional major adverse cardiovascular events.